Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors

Figure 1

Percentage of patients achieving a response according to biologic treatment number. Bar graphs showing the percentage of patients achieving a response to any biologic disease-modifying antirheumatic drug (DMARD) according to criteria commonly used in rheumatoid arthritis (RA) patients, separated by number of biologic DMARDs to which the patients were exposed. With regard to the ACR categories, ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively. ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; DAS28, Disease Activity Score 28 joint count.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us